呼吸道合胞病毒亚单位疫苗的研究
|
摘要
呼吸道合胞病毒(Respiratory syncytial virus,RSV)属副黏病毒科,肺炎病毒属,为非节段性的负链RNA病毒。RSV基因组有15,222个核苷酸,主要编码10个特异性蛋白,其中膜表面的融合蛋白F和粘附蛋白G是激发机体产生保护性抗体的最主要的病毒表面抗原,是疫苗研究开发的重要内容。呼吸道合胞病毒(RSV)广泛流行于世界各地,是引起婴幼儿下呼吸道感染最常见的病原微生物之一。世界卫生组织(WHO)已将RSV疫苗列为全球疫苗计划中优先发展的疫苗之一。RSV疫苗研制虽已有40年历史,但至今尚无被批准使用的疫苗。为此,本研究利用杆状病毒昆虫表达系统表达了RSV全长的F、G蛋白,免疫Balb/c小鼠,评价了F和G全长蛋白疫苗的免疫原性和有效性。运用生物信息学软件选择F205～223,255～278,G142～204位氨基酸作为研究对象,表达并纯化了F-G融合表位蛋白。该研究为进一步研制适合我国的RSV疫苗奠定了试验基础。
RSV F和G全长重组蛋白疫苗的质粒构建、表达和纯化目的表达并纯化RSV Long株F和G全长蛋白。方法采用反转录聚合酶链反应(RT-PCR)克隆了RSV A型Long株的全长F和G基因,构建了F-pFastHT A和G-pFastHT A质粒。将阳性重组质粒分别转化DH10Bac感受态细胞,获得重组杆状病毒质粒F-Bacmid和G-Bacmid。将其转染昆虫细胞,成功包装了含有目的片段的重组杆状病毒,采用Ni2+离子亲和层析柱纯化了接毒细胞的表达产物。进行SDS-PAGE电泳、间接免疫荧光和Western-blot试验鉴定重组蛋白。结果目的蛋白F和G在昆虫细胞中有特异性表达, Ni2+离子亲和层析柱能够很好的吸附重组目的蛋白。结论成功克隆了RSV F和G基因,并在Sf9昆虫细胞中获得表达。Ni2+离子亲和层析法纯化目的蛋白的纯度达85%以上,可用于免疫Balb/c小鼠。
RSV F和G全长重组蛋白和表位肽疫苗免疫效果的研究目的检测RSV F和G蛋白候选疫苗的免疫原性和安全性。方法选用Mf59分别与F、G蛋白配制疫苗滴鼻免疫Balb/c小鼠;弗氏佐剂与F和G蛋白配制疫苗肌肉注射免疫Balb/c小鼠做为对照。分别采用间接ELISA法和微量中和试验检测免疫鼠血清特异性IgG和中和抗体效价;间接ELISA法检测免疫鼠肺、鼻灌洗液特异性IgG和SIgA抗体效价;MTT法检测免疫鼠脾淋巴细胞增殖;ELISPOT法检测免疫鼠脾脏淋巴细胞γ-IFN、IL-2、IL-4分泌。结果经杆状病毒昆虫表达系统表达的RSV F和G全长蛋白在Balb/c小鼠体内诱导产生了高滴度的血清IgG抗体、中和抗体和肺局部抗体,其中F蛋白疫苗诱导产生了平衡的IgG1/IgG2a。结论RSV F蛋白可刺激机体产生体液免疫和细胞免疫;G蛋白疫苗只刺激机体产生体液免疫,并引起Th2优势应答。
RSV F-G表位肽疫苗的质粒构建、表达及纯化目的选择能同时刺激机体产生细胞免疫和体液免疫并诱导平衡的Th1/Th2应答的RSV表位蛋白。方法运用生物信息学软件预测F和G蛋白的空间结构,并查看资料寻找F和G蛋白的抗原表位。选择F205～223,255～278,G142～204位氨基酸作为研究对象,合成编码这两段表位的基因,采用重叠PCR将编码F和G两段表位的基因连接,杆状病毒昆虫表达系统表达F-G融合表位肽蛋白,Ni2+亲和层析纯化目的蛋白。结果融合表位蛋白F-G在昆虫细胞中有特异性表达, Ni2+离子亲和层析柱能够很好的吸附重组目的蛋白。结论成功克隆了RSV F-G融合表位基因,并在Sf9昆虫细胞中获得表达。Ni2+离子亲和层析法纯化目的蛋白的纯度达85%以上。
Respiratory syncytial virus (RSV) is a kind of non-segmental RNA virus of negative strand, and it is classified as a member of the genus Pneumonia virus in the family of Paramyxoviridae. RSV genome has 15,222 nucleotides mainly coding 10 specific proteins, the fusion protein F on membrane surface and adhesion protein G, as the important aspect of research and development in vaccination, are the mainly surface antigens of RSV to induce the production of protective antibodies. RSV is one of the most common pathogen which cause the lower respiratory tract infection called asthmatic suffocating pneumonia(ASP) of newborns and infant widespread over the world.As the major respiratory pathogen in China, it makes ASP outbreak in every years.
So far, RSV infection is still the primary cause of hospitalization of the infants so that the production of RSV Vaccines had been included in the global plans by WHO as one of the priority products. There is no licensed RSV vaccine after 40 years development. In this study, RSV fusion protein F and adhesion protein G have been successfully produced as RSV subunit vaccine candidate with baculovirus-Insect expression system. The immunogenicity and dffectivity of the RSV subunit vaccine candidate have been evaluated after inoculation in Balb/c mice. Amino acids of 205-223 and 255-278 from F ptotein, and 142-204 from G protein were selected to be epitopes analyzed by bioinformatic software. Epitope fusion protein of F and G have been expressed and purified successfully. It is helpful for further devolepment of RSV subunit vaccine in China.
Recombinant plasmid construction, expression and purification of RSV complete F protein and G protein objective expression and purification of F and G gene of RSV (A type, Long strain). Methods F and G full gene of RSV (A type, Long strain) were amplified by RT-PCR, and the plasmid of F-pFastHT A and G-pFastHT A were constructed.The positive purified recombinant plasimid was transformed into DH10Bac E. coli for transposition into the bacmid to get F-Bacmid and G-Bacmid, respectively. The positive purified recombinant bacmids have been transfected into insect cell for successful virus packing. Product of the transfected cells were purified by Ni2+ Ion affinity chromatography and the expression of protein were detected by SDS-PAGE assay, Indirect immunofluorescence and and western-blot assay. Results The interest protein ( F and G) were expressed of specificity and absorbed efficiently by the Ni2+ affinity chromatograph column.
Conclusion F gene and G gene were cloned successfully and proteins were expressed in insect cells. The purity was up to 85% by Ni2+ Ion affinity chromatography purification that it was fit for immunization to Balb/c mice.
Evaluation of immune effect of recombinant protein of complete F protein and G protein and RSV subunit vaccine candidate Objective to exam the immunogenicity and safety of the vaccine candidates of F and G protein of RSV. Methods F protein and G protein were immuned intranasally to Balb/c mice with Mf59 respectively as vaccine candidates and intramuscularly with Freund's adjuvant respectively as control. The specific IgG and neutralizing antibody titers of immune mouse serum were determined Separately by indirect ELISA and micro neutralization test; the titers of specific IgG and IgA of lung lavage fluid and nasal lavage fluid were detected by indirect ELISA in immune mouse; multiplication of splenic lymphocyte was detected by MTT assay; secretion ofγ-IFN,IL-2 and IL-4 were detected by ELISPOT assay. Results Serum IgG, neutralizing antibodies and lung local antibodies of high titers were produced in Balb/c mice by induction F protein and G protein expressed in insect baculovirus expression system. Balanced IgG1/IgG2a was induced by F protein also. Conclusion F protein could induce the humoral immunity and cell-mediated immunity, G protein only induce humoral immunity and the advantage response of Th2 cells.
Recombinant plasmid construction, expression and purification of RSV F-G epitope fusion protein Objective Choosing the protein epitope that could induce humoral immunity and cell-mediated immunity simultaneously and induce the balanced Th1/Th2 response also.Methods The spatial structure of F and G protein were analyzed and forecasted and epitopes of F and G protein was found by using software of bioinformatics.205aa-223aa and 255aa-278aa of F protein and 142aa-204aa of G protein were selected and their coding gene of F and G epitope were synthesized and linked with G2SG2 by overlapping PCR. Then F-G fusion epitope protein was expressed in insect cells and purified by Ni2+ affinity chromatograph. Results Specific recombinant fusion epitope protein F-G was expressed in insect cells, and absorbed efficiently by the Ni2+ affinity chromatograph column for purification. Conclusion RSV fusion epitope gene was cloned successfully and the fusion epitope protein F-G was expressed in Sf9 insect cells. The putity of the inteset fusion protein was up to 85% by Ni2+ Ion affinity chromatography.
RSV F和G全长重组蛋白疫苗的质粒构建、表达和纯化目的表达并纯化RSV Long株F和G全长蛋白。方法采用反转录聚合酶链反应(RT-PCR)克隆了RSV A型Long株的全长F和G基因,构建了F-pFastHT A和G-pFastHT A质粒。将阳性重组质粒分别转化DH10Bac感受态细胞,获得重组杆状病毒质粒F-Bacmid和G-Bacmid。将其转染昆虫细胞,成功包装了含有目的片段的重组杆状病毒,采用Ni2+离子亲和层析柱纯化了接毒细胞的表达产物。进行SDS-PAGE电泳、间接免疫荧光和Western-blot试验鉴定重组蛋白。结果目的蛋白F和G在昆虫细胞中有特异性表达, Ni2+离子亲和层析柱能够很好的吸附重组目的蛋白。结论成功克隆了RSV F和G基因,并在Sf9昆虫细胞中获得表达。Ni2+离子亲和层析法纯化目的蛋白的纯度达85%以上,可用于免疫Balb/c小鼠。
RSV F和G全长重组蛋白和表位肽疫苗免疫效果的研究目的检测RSV F和G蛋白候选疫苗的免疫原性和安全性。方法选用Mf59分别与F、G蛋白配制疫苗滴鼻免疫Balb/c小鼠;弗氏佐剂与F和G蛋白配制疫苗肌肉注射免疫Balb/c小鼠做为对照。分别采用间接ELISA法和微量中和试验检测免疫鼠血清特异性IgG和中和抗体效价;间接ELISA法检测免疫鼠肺、鼻灌洗液特异性IgG和SIgA抗体效价;MTT法检测免疫鼠脾淋巴细胞增殖;ELISPOT法检测免疫鼠脾脏淋巴细胞γ-IFN、IL-2、IL-4分泌。结果经杆状病毒昆虫表达系统表达的RSV F和G全长蛋白在Balb/c小鼠体内诱导产生了高滴度的血清IgG抗体、中和抗体和肺局部抗体,其中F蛋白疫苗诱导产生了平衡的IgG1/IgG2a。结论RSV F蛋白可刺激机体产生体液免疫和细胞免疫;G蛋白疫苗只刺激机体产生体液免疫,并引起Th2优势应答。
RSV F-G表位肽疫苗的质粒构建、表达及纯化目的选择能同时刺激机体产生细胞免疫和体液免疫并诱导平衡的Th1/Th2应答的RSV表位蛋白。方法运用生物信息学软件预测F和G蛋白的空间结构,并查看资料寻找F和G蛋白的抗原表位。选择F205～223,255～278,G142～204位氨基酸作为研究对象,合成编码这两段表位的基因,采用重叠PCR将编码F和G两段表位的基因连接,杆状病毒昆虫表达系统表达F-G融合表位肽蛋白,Ni2+亲和层析纯化目的蛋白。结果融合表位蛋白F-G在昆虫细胞中有特异性表达, Ni2+离子亲和层析柱能够很好的吸附重组目的蛋白。结论成功克隆了RSV F-G融合表位基因,并在Sf9昆虫细胞中获得表达。Ni2+离子亲和层析法纯化目的蛋白的纯度达85%以上。
Respiratory syncytial virus (RSV) is a kind of non-segmental RNA virus of negative strand, and it is classified as a member of the genus Pneumonia virus in the family of Paramyxoviridae. RSV genome has 15,222 nucleotides mainly coding 10 specific proteins, the fusion protein F on membrane surface and adhesion protein G, as the important aspect of research and development in vaccination, are the mainly surface antigens of RSV to induce the production of protective antibodies. RSV is one of the most common pathogen which cause the lower respiratory tract infection called asthmatic suffocating pneumonia(ASP) of newborns and infant widespread over the world.As the major respiratory pathogen in China, it makes ASP outbreak in every years.
So far, RSV infection is still the primary cause of hospitalization of the infants so that the production of RSV Vaccines had been included in the global plans by WHO as one of the priority products. There is no licensed RSV vaccine after 40 years development. In this study, RSV fusion protein F and adhesion protein G have been successfully produced as RSV subunit vaccine candidate with baculovirus-Insect expression system. The immunogenicity and dffectivity of the RSV subunit vaccine candidate have been evaluated after inoculation in Balb/c mice. Amino acids of 205-223 and 255-278 from F ptotein, and 142-204 from G protein were selected to be epitopes analyzed by bioinformatic software. Epitope fusion protein of F and G have been expressed and purified successfully. It is helpful for further devolepment of RSV subunit vaccine in China.
Recombinant plasmid construction, expression and purification of RSV complete F protein and G protein objective expression and purification of F and G gene of RSV (A type, Long strain). Methods F and G full gene of RSV (A type, Long strain) were amplified by RT-PCR, and the plasmid of F-pFastHT A and G-pFastHT A were constructed.The positive purified recombinant plasimid was transformed into DH10Bac E. coli for transposition into the bacmid to get F-Bacmid and G-Bacmid, respectively. The positive purified recombinant bacmids have been transfected into insect cell for successful virus packing. Product of the transfected cells were purified by Ni2+ Ion affinity chromatography and the expression of protein were detected by SDS-PAGE assay, Indirect immunofluorescence and and western-blot assay. Results The interest protein ( F and G) were expressed of specificity and absorbed efficiently by the Ni2+ affinity chromatograph column.
Conclusion F gene and G gene were cloned successfully and proteins were expressed in insect cells. The purity was up to 85% by Ni2+ Ion affinity chromatography purification that it was fit for immunization to Balb/c mice.
Evaluation of immune effect of recombinant protein of complete F protein and G protein and RSV subunit vaccine candidate Objective to exam the immunogenicity and safety of the vaccine candidates of F and G protein of RSV. Methods F protein and G protein were immuned intranasally to Balb/c mice with Mf59 respectively as vaccine candidates and intramuscularly with Freund's adjuvant respectively as control. The specific IgG and neutralizing antibody titers of immune mouse serum were determined Separately by indirect ELISA and micro neutralization test; the titers of specific IgG and IgA of lung lavage fluid and nasal lavage fluid were detected by indirect ELISA in immune mouse; multiplication of splenic lymphocyte was detected by MTT assay; secretion ofγ-IFN,IL-2 and IL-4 were detected by ELISPOT assay. Results Serum IgG, neutralizing antibodies and lung local antibodies of high titers were produced in Balb/c mice by induction F protein and G protein expressed in insect baculovirus expression system. Balanced IgG1/IgG2a was induced by F protein also. Conclusion F protein could induce the humoral immunity and cell-mediated immunity, G protein only induce humoral immunity and the advantage response of Th2 cells.
Recombinant plasmid construction, expression and purification of RSV F-G epitope fusion protein Objective Choosing the protein epitope that could induce humoral immunity and cell-mediated immunity simultaneously and induce the balanced Th1/Th2 response also.Methods The spatial structure of F and G protein were analyzed and forecasted and epitopes of F and G protein was found by using software of bioinformatics.205aa-223aa and 255aa-278aa of F protein and 142aa-204aa of G protein were selected and their coding gene of F and G epitope were synthesized and linked with G2SG2 by overlapping PCR. Then F-G fusion epitope protein was expressed in insect cells and purified by Ni2+ affinity chromatograph. Results Specific recombinant fusion epitope protein F-G was expressed in insect cells, and absorbed efficiently by the Ni2+ affinity chromatograph column for purification. Conclusion RSV fusion epitope gene was cloned successfully and the fusion epitope protein F-G was expressed in Sf9 insect cells. The putity of the inteset fusion protein was up to 85% by Ni2+ Ion affinity chromatography.
引文
1 Zhang W,Yang H,Kong X,et al.Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene[J].NatMed,2005,11(1): 56-62
2 Spann KM,Tran KC,Collins PL.Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor3, NF-kappaB,and proinflammatory cytokines[J].Virol,2005,79(9):5353-5362.
3 Murphy LB,Loney C,Murray J,et al.Investigations into the aminoterminal domain of the respiratory syncytial virus nucleocap sid protein reveal elements important for nucleocap sid formation and interaction with the phosphor protein[J].Virology,2003,307(1):143-153.
4 Lu B,Ma CH,Brazas R,et al.The major phosphorylation sites of the respiratory syncytial virus phosphop rotein are dispensable for virus rep lication in vitro[J].Virol,2002, 76(21):10776-10784.
5 Bukreyev A,Whitehead SS,Murphy BR,et al.Recombinant respiratory syncytial virus from which the entire SH gene has bee deleted grows efficiently in cell culture and exhibits site2secific attenuation in the respiratory tract of the mouse[J].Virol,1997,71(12): 8973-8982.
6李光,井申荣.呼吸道合胞病毒蛋白的研究进展[J].中国生物制品杂志,2006,19(5):541-547.
7 Rodriguez L,Cuesta I,Asenjo A,et al.Human resp iratory syncytial virus matrix protein is an RNA-binding protein:binding properties,location and identity of the RNA contact residues[J].Gen Virol,2004,85(3):709-719.
8 Tang RS,Nguyen N, Cheng X,et al.Requirement of cysteines and length of the human respiratory syncytial virusM2-1 protein for protein function and virus viability[J].Virol,2001,75(23):11328-11335.
9 Teng MN,Whitehead SS,Bermingham A,et al.Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees[J].Virol,2000,74(19):9317-9321.
10 Blount RE, Morris JA,Savage RE.Recovery of cytopqthogenic agent from chinmpanzees with coryza[J].Proc Soc Exp Biol Med,1956,92(3):544-549.
11曾瑞红.RSV重组蛋白疫苗的制备及其免疫原性和保护性研究[J].军事医学科学院博士学位论文,2006:6.
12 Mohamed H,Caroline B.Respiratory syncytial virus in healthy adults:the cost of a cold[J].J Clin Vir,2003,27:14 - 21.
13范行良,周铁群.呼吸道合胞病毒F蛋白研究进展[J].微生物学免疫学进展,2004,32(4):73-76.
14芦起,谢正德,申昆玲.呼吸道合胞病毒的蛋白特征及抗原变异[J].国外医学病毒学分册,2005,12(3):76-80.
15 L.Goetsch,H.Plotnicky-Gilquin,J.P.Aubry,et al.BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice[J].Vaccine,2001(19):4036-4042.
16 Beeler JA,Van Wyke CK.Neutralization epitopes of the F glycoprotein of respiratory syncytial virus:effect of mutation upon fusion functio〔J〕Virol,1989,63(7): 2941-2950.
17孔晓慧,江载芳.人类呼吸道合胞病毒粘附(G)蛋白的研究进展[J].国外医学分册,1999,6(3):77-81.
55李忠明.当代新疫苗学[M].高等教育出版社,2001.
19丁媛,赵晓东.机体抗呼吸道合胞病毒免疫机制研究进展[J].国际儿科学杂志,2006,33(1)志:14-17.
20 Gill MA,Palucka KA,Barton T,et al.Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytialvirus and other viral respiratory infections[J].J Infect Dis,2005,191(7):1105-1115.
21 Murphy BR,et al.Immunization of cotton ratsw ith the fusion(F) and large (G)glycol proteins of respiratory syncytial virus protects against respiratory syncytial virus challenge without potenting RSV disease[J].Vaccine,1989,7(6):533～540.
22 Bendelja K,Gagro A,Bace A,et a1.Predominant type-2 response in infants with respiratory syncytial virus(RSV)infection demonstrated by cytokine flow Cytometry[J].Clin Exp Immunol,2000,121(2):332-338.
23 Elliott MB,Tebbey PW,Pryharski KS,et al.Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES(CCL5)[J].J Med Virol,2004,73(2):300-308.
24 Kollerl MF,Graul T,Christen P.Induction of antibodies agaist murine full-length prion protein in wild-type mice[J].J of Neuroimmunology,2002,132:113-116.
25 Binde RJ,Han DK,Srivastava PK.CD91:a receptor for heat shock protein gp96[J].Nat Immunol,2000,1:151-155.
26 Srivastava PK,Amato RJ.Heat shock proteins:the‘Swiss Army Knife’vaccines againstcancers and infectious agents.Vaccine,2001,19:2590-2597.
27林林,王佑春,李富德.呼吸道合胞病毒(RSV)感染预防的研究进展[J].国外医学病毒学分册,2003,10(3):82-89.
28周娟,崔玉霞,杨锡强,等.特异性反义寡核苷酸抗小鼠呼吸道合胞病毒感染的研究[J].第三军医学学报,2007,29(2):112-116.
29崔玉霞,杨锡强.呼吸道合胞病毒感染及反义基因治疗的研究进展[J].中华儿科杂志,2006, 44(8):629-632.
30 Yu JY,Deruiter SL,Tumer DL.RNA interference by expression of short interfering RNAs and hairpin RNAs in mammalian cells[J].Proc Natl Acad Sci USA,2002,99: 6047-6052.
31 Plotnicky H,Siegrist CA,Aubry JP,et al.Enhanced pulmonary immunopathology following neonatal priming with formalin-inativated respiratory syncytial virus but not with the BBG2Na vaccine candidate[J].Vaccine,2003,21:2615-2660.
32 Hancock GE ,Heers KM,Pryharski KS,et al . Adjuvants recognized by Toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytialvirus[J]. Vaccine ,2003,21(27- 30):4348-4358.
33 Olson MR,Varga SM.Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease[J].J Immunol,2009,182(5):3024-3031.
34 Julian P.Legg,Imran R.Hussain,Jill A.Warner, et al.Type 1 and Type 2 Cytokine Imbalance in Acute Respiratory Syncytial Virus Bronchiolitis[J].AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,2003,168:633-639.
35 F.Eun-Hyung Lee,Edward E.Walsh,Ann R.Falsey, Human Infant Respiratory Syncytial Virus(RSV)–Specific Type 1 and 2 Cytokine Responses Ex Vivo during Primary RSV Infection[J].JID,2007,195(15):1779-1788.
36 Marc PG,Thomas C,Yuri P,et al.A review of vaccine research and development:Human acute respiratory infections[J].Vaccine,2005,23:5708.
37芦起,谢正德,许文波,等.呼吸道合胞病毒亚单位疫苗的研究进展[J].世界核心医学期刊文摘·儿科学,2005,1(9):1-4.
38 Tristram DA,Welliver RC,Mohar CK,et al. Immunogenicity and safety of respiratory syncytial virus virus subunit vaccine in seropositive children 18-36 months old[J]. Infect Dis,1993,167:191-195.
39 Falsey A R. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine(PFP-2)in the institutionalized elderly[J].Vaccine,1997,15(IO): 1130-1132.
40 Munoz.F M. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women[J].Vaccine 2003,21:3465-3467.
41 Hancock GE,Smith JD,Heers KM.Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus[J].Infect Dis,2000,81:1786-1771.
42 Piedra PA,Cron SG, JewellA, et al.Immunogenicity of a new purified fusionprotein vaccine to respiratory syncytial virusa multi2center trial in childrenwith cystic fibrosis[J].Vaccine,2003,21(19-20):2448-2460.
43 Kim HJ,Kim JK,Seo SB,et.al.Intranasal vaccination with peptides and cholera toxin subunit B as adjuvant to enhance mucosal and systemic immunity to respiratory syncytial virus[J].Arch Pharm Res,2007,30(3):366-371.
44 Shree R.Singh.Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model[J].Vaccine,2007,14:6211-6223.
45 Zhan X,Hurwitz JL,Krishnamurthys,et,al.Respiratory syncytial virus(RSV)fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B[J]. Vaccine,2007,25(52):8782-8793.
46 Power UF,Nguyen TN,Rietveld E,et al.Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine(BBG2Na) in healthy young adults[J].J Infect Dis,2001,184:1456-1460.
47徐军,胡云章.呼吸道合胞病毒疫苗研究进展.生物技术通讯,2007,18(2):310-312.
48 Power UF,Plotnicky H,Blaecke A,et al.The immunogenicity,protective efficacy and safety of BBG2Na,a subunit respiratory syncytial virus(RSV) vaccine candidate, against RSV-B,Vaccine,2003,22:168-176
49 De Waal L,Brideau RJ,Thomsen DR,et al.Evaluation of BBG2Na in infant macaques:specific immune responses after vaccination and RSV challenge[J].Vaccine,2004,22:915-922.
50 Prince GA,Denamur F,Deschamps M,et al.Monophosphoryl lipid Aadjuvant reverses a principalhistologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease[J].Vaccine 2001,19(15-16):2048-2054.
51 Klinguer-Hamour C,Libon C,Plotnicky-Gilquin H,et al. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine[J].Vaccine 2002,20(21-22):2743-2751.
52 Huang Y. Anderson R Enhanced immune protection by a liposomeencap sulated recombinant respiratory syncntial virus(RSV) vaccine using immunogenic lipids from Deinococcus radiodurans[J].Vaccine,2002,20(11-12):1586-1592.
53 Roux X. Sub-Nucleocapsid Nanoparticles:A Nasal Vaccine against Respiratory Syncytial Virus[J].PLoS ONE,2008,3(3):1766.
54 Matthews N C,Power U F,Reen D J.Neonatal human autologous dendritic cells pulsed with recombinant protein antigen prime the generation of non-polarized CD4 T-cell effectors[J].Int Immunol,2007,19(6):703-712.
55 Yusibov V,Mett V,Mett V,et al.Peptide-based candidate vaccineagainstrespiratory syncytial virus[J].Vaccin,2005,23(17/18):2261-2265.
56 Ward TM.Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic[J].Gen Virol,2008,89(3):741-750.
57 Wathen MW, Brigeau RJ.Thomsen DR, et al.Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector [J].Gen virol 1989,70:2625-2635.
58 Prince GA,Capiau C,Deschamps M,et al.Efficacy and safety studies of studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats [J].Virol 2000,74:10287-10292.
59 Oien NL,Brideau RJ,Thomsen DR,et al.Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity[J].Vaccine 1993,11:1040-1048.
60 Oien NL,Brigeau RJ,Walsh EE, et al.Induction of local and systemic immunity against human respiratory syncytial virus using chimeric FG glycoprotein and cholera toxin B subunit[J].Vaccine,1994,12:731-735.
61 Polack FP,Karron RA. The future of respiratory syncytial virus vaccine development[J]. Pediatr Infect Dis,2004,23(1):65-73.
62 Juhasz K,Whitehead ss,Bui RT,et al.The temperature-sensitive(ts) phenotype of a cold-passaged(cp) live attenuated respiratory syncytial virus vaccine candidate,designated cpts530,result S from a single amino acid substitution in the L Protein[J].J virol,1997,71(8):5814-5819
63 Gonzalez IM,Karron RA,Eichelberger M,et al.Evaluation of the live attenuated cpts
248/404 RSV Vaccine in ombination vith a subunit RSV vaccine(PFP-2)in healthy young and older adults[J].Vaccine,2000,18(17):1763-1772.
64 Crowe JE, Randolph V.Murphy BR.The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees,but exhibits partial loss of the ts phenotype following relication in vivo[J].Virus Res,1999,59(1):13-22.
65 Whitehead SS,Bukreyev A,Teng MN,et al.Recombinant respiratory syncytial virus bearing a deletion of either the or SH gene is attenuated in chimpanzees[J],J Virol,1999,73(4):3438-3442.
66 TengMN,Whitehead SS,Bermingham A,et al.Recombinant respiratory syncytial virus that does not express the NS1or M2-2 protein is highly attenuated and immunogenic in chimpanzees[J].J Virol,2000,74(19):9317-9321.
67 Rodriguez WJ,Gruber WC,Welliver RC,et al.Respiratory syncytial virus(RSV)immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections:Respiratory Syncytial Virus Immune Globulin Study Group[J].Pediatrics,1977,99(3):454-461.
68 Whitehead SS, HillMG, Firestone CY,et al.Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup Awith those of subgroup B generates chimeric live attenuated RSVsubgroup B vaccine candidates[J].J Virol,1999,73 (12) : 9773-9780.
69 OlszewskaW,Suezer Y,Sutter G,et al.Protective and disease2enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins[J].Vaccine,2004,23(2):215-221.
70 Sandhu JS,rasnyansk i SF,Dom ier LL,et al.T ransgenic Res,2000,9(2):127-135
71 Bembridge GP,Rodriguez N,Garcia-Beato R,et al.Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment(G)protein[J]. Vaccine,2000, 19(9210):1038-1046.
72苏荣,王立波.呼吸道合胞病毒疫苗的研究进展[J].国际儿科学杂志,2006,33(3):187-190.
73吴小锋,岳万福,刘剑梅,等.Bac-to-Bac系统的研究进展及在家蚕中的应用[J].蚕业科学, 2007,33(1):146-150.
74 Gerald E.Hancock,Honeoye Falls,Paul W.Tebbey,et al.Enhanced immune response to attachment (G) protein of respiatory syncytial virus[P].US:6,699,478,2004,2.
75刘菊,杨春,唐安芬,等.呼吸道合胞病毒Long株的培养及应用[J].微生物学杂志,2004, 24(5):47-49.
76 Pammivenkatesh M, Weisman LE. Prevention and treatment of respiratory syncytial virus infection infants:an update[J].Expert Rev Vaccine,2006,5(2):261-268.
77卢圣栋主编.现代分子生物学实验技术[M].第二版.北京:中国协和医科大学出社,1999, 80-149,233-292.
78 Subel FM,Brent R,Kingston RE,et al.精编分子生物学实验指南[M],北京:科学出版社,1998.
79 Simoes EA ,Carbonell - Estrany X.Impact of severe disease caused by respiratory syncytial virus in children living in developed countries[J].Pediatr Infect Dis J,2003,22(2):13-18.
80曾瑞红,龚伟,梅兴国,等.呼吸道合胞病毒重组蛋白DsbA2G1F/M2的制备方法及免疫原性研究[J].中国药学杂志,2007,42(2):90-93.
81 M c Into sh K,Chanock R. Resp irato ry Syncytial V irus B N F ields et al[J]. Virology Raven Press, New York.1990,1045-1072.
82 Welliver R C.Respiratory syncytial virus and other Respiratory viruses[J].Pediatr Infect Dis J,2003,22(2):6～12.
83袁媛,何金生,张梅,等.人呼吸道合胞病毒F基因的克隆、真核表达与鉴定[J].免疫学杂志,2006,22(3):330-333.
84 Johnson T R,TengM N, Collins PL,et al.Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine2enhanced disease induced by immunization with formalin inactivated RSV[J].J Virol,2004,78(11):6024-6032.
85 Cane P A ,Matthews D A ,Pringle C R. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial virus[J].J Gen Virol, 1991,72:2091-2096.
86 Cane P A. Molecular epidemiology of respiratory syncytial virus[J].Rev Med Virol, 2001,11(2):103-316.
87 Plotnicky-Gilquin H,Cyblat-Chanal D,Aubry JP,et al.Gamma interfereon dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment[J].J Virol,2002,76(20):10203.
88 IMartinez,J Dopazo and J A Melero. Antigenic structure of the human respiratory syncytial virus Gglyxoprotein and relevance of hypermutation events for the generation of antigenic variants[J].Journal of General virology 1997,78:2419.
89 Kneyber M C, Kimpen J L. Advances in respiratory syncytial virus vaccine development [J].Curr Opin Investig Drugs,2004,(5):163-170.
90耿学辉,王之梁,钱渊,等.呼吸道合胞病毒北京地区分离株G蛋白的基因分析[J].1996,12(4):317-322.
91邓洁,孙晓鸥,钱渊,等.中国呼吸道合胞病毒地方株G蛋白在重组痘苗病毒中的表达[J].中华微生物学和免疫学杂志,2004,24(4):284-286.
92邓洁,王之梁,钱渊,等.我国流行性喘憋性肺炎呼吸道合胞病毒分离株F蛋白基因特征初探[J].中华儿科杂志,1999 37(5):287-290.
93曾瑞红,梅兴国,龚伟,等.RSV CTL表位与G蛋白片段的融合表达对G蛋白片段诱导的免疫应答的调节作用[J].分子与细胞免疫学,2007,23(5):387-390.
94曾瑞红,梅兴国.RSV CTL表位与G蛋白片段的融合表达对G蛋白片段诱导的免疫应答的调节作用[J].中国免疫学杂志,2007,23(5):387-390.
95熊蕊,邓国华,黎玉梅,等.H5亚型禽流感病毒HA基因杆状病毒载体的构建[J].黑龙江畜牧兽医,2007(5):15-17.
96 MARK PARRINGTON,STEPHEN COCKLE.Baculovirus Expression of the Respiratory Syncytial Virus Fusion Protein using Trichoplusia ni Insect Cells.Virus Genes[J].Virus Genes,1997,14(1):63-72.
97 Hancock GE,Heers KM. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)[J].Vaccine.2001,19(32):4874-4882.
98顿继凤,周迎春,蒲娟,等.H5N1亚型禽流感病毒血凝素在昆虫杆状病毒系统中表达与活性鉴定[J].农业生物技术学报,2007,15(4):547-551.
99贾珊珊,孙凌霜,齐岩,等.H7亚型禽流感病毒HA1基因在重组杆状病毒中的表达及其表达产物的抗原性[J].中国兽医科学,2007,37(3):232-235.
100袁建琴,高斌战,宋宝敏.H9N2型禽流感病毒HA基因在昆虫/杆状病毒系统中的表达[J].山西农业大学学报(自然科学版),2007,27(1):71-74.
101 Elisa H.Fleming,Andrey A.Kolokoltsov,Robert A.Davey,et al.Respiratory Syncytial Virus F Envelope Protein Associates with Lipid Rafts without a Requirement for Other Virus Proteins[J].JOURNAL OF VIROLOGY,2006,80(24):12160-12170.
102汪家政,范明主编.蛋白质技术手册[M].北京:科学出版社.2008.8.
103 Christine Krempl,Brian R.Murphy,Peter L.Collins.Recombinant Respiratory Syncytial Virus with the G and F Genes Shifted to the Promoter-Proximal Positions[J].JOURNAL OF VIROLOGY,2002,76(23):11931-11942.
104林董.RSV五个基因及GFP-CP、GFP-SP融合基因在Sf9昆虫细胞中的表达[D].福建:福建农林大学,2007.
105 Power U F,Plotnicky-Gilquin H, Huss T et al.Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment[J].Virology,1997, 230:155-166.
106殷震,刘景华主编.动物病毒学[M].第二版.北京:科学出版社,P329-331.
107 Patricia Sastre,Antonius G.P.Oomens,Gail W.Wertz.The stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein[J]. Vaccine,2007,(25):5025-5033.
108朱立平.免疫学常用实验方法[M].北京:民军医出版社,2000.
109 Janak A.Patel,Dang T.Nguyen,Krystal Revai,et al.Role of respiratory syncytial virus in acute otitis media:Implications for vaccine development[J].Vaccine, 2007,25:1683—1689.
110 R.Marsh,A.Connor,E.Gias,et al.Increased Susceptibility of Human Respiratory Syncytial Virus to Neutralization by Anti-Fusion Protein Antibodies on Adaptation to Replication in Cell Culture[J].Journal of Medical Virology 2007(79):829-837.
111 Sonya L.Cyr,Taff Jones,Ioana Stoica-Popescu.C57Bl/6 mice are protected from respiratory syncytial virus (RSV)challenge and IL-5 associated pulmonaryeosinophilic infiltratesfollowing intranasal immunization with Protollin-eRSV vaccine[J].Vaccine,2007,(25):3228-3232.
112韩岳,王希良,董梅,等.tPA信号肽和鼠疫杆菌保护性抗原V融合基因的构建及免疫效果鉴定[J].现代免疫学,2006,26(6):477-482.
113韩岳,王希良,董梅,等.鼠疫菌重组质粒pcDNATEPF12V的构建及其免疫效果的研究[J].免疫学杂志,2005,21(3):208-211.
114吕进,张松乐,董梅.炭疽AVA疫苗特异性抗体分泌细胞检测方法的建立[J].免疫学杂志, 2007,23(4):452-455.
115 Whitmire J K,Asano M S Murali-Krishna K,et al.Long term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infection[J].J Virol,1998, 72(10):8281—8288.
116 Openshw PJW.Immunity and immunopathology to respiratory sycytial virus:the mouse modl[J]e.Am J Respir Crit Care Med,1995,152:59-62.
117董德祥主编.疫苗技术基础与应用[M].北京:化学工业出版社,2003,102-148.
118曾瑞红,梅兴国,龚伟,等.RSV CTL表位与G蛋白片段的融合表达对G蛋白片段诱导的免疫应答的调节作用[J].分子与细胞免疫学,2007,23(5):387-390.
119 Sonya L.Cyr,Taff Jones,Ioana Stoica-Popescu,et al.Intranasal proteosome-based respiratory syncytial virus (RSV)vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology[J].Vaccine,2007,25,5378-5389.
120 Elliott MB ,Tebbey PW,Pryharski KS ,et al.Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES(CCL5)[J].J Med Virol,2004,73(2):300-308.
121 Mosmann T R,Sad S.The expanding universe of T-cell subset:Th1,Th2 and more[J]. Immunol Today,1996,17:138-146.
122 Shirai A,Homes K,Klinman D M,et al.Detection and quantitation of cells secreting IL26 under physiologic conditions in BALB/c mice[J].Immunol,1993,150:793-799.
123毕爱华主编.医学免疫学[M].北京:民解放军出版社,1997,24-92.
124 Kolaskar AS,Tongaonkar PC A semi-empirical method for prediction of antigenic determinants on protein antigens[J].FEBS Lett.1990,276(1-2):172-174.
125 Alexander Bukreyev,Maria Elina Serra,Federico R.Laham,et,al.The Cysteine-Rich Region and Secreted Form of the Attachment G Glycoprotein of Respiratory Syncytial Virus Enhance the Cytotoxic T-Lymphocyte Response despite Lacking Major Histocompatibility Complex Class I-Restricted Epitopes[J].Journal of Virology,June 2006,80(12):5854-5861.
126 Jennifer Harcourt, Rene Alvarez, Les P. Jones,et al.Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses[J].The Journal of Immunology,2006,176:1600-1608.
127 Ultan F.Power,Liliane Goetsch,Thierry Champion,et al.Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein[J].Vaccine,2001,19:2345-2351.
128王云飞,曾瑞红,梅兴国.免疫A型呼吸道合胞病毒G75-225蛋白的小鼠对病毒感染的抗性[J].生物技术通讯,2006,17(3):352-354.
129余莉,龚蕴贞.呼吸道合胞病毒模拟表位合成肽疫苗的开发[J].国外医学预防诊断治疗用生物制品分册,2002,25(5):199-201.
130 ANON SRIKIATKHACHORN,WILBUR CHANG,THOMAS J.BRACIALE.Induction of Th-1 and Th-2 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope and Major Histocompatibility Complex Independent[J].JOURNAL OF VIROLOGY,1999, 73(8):6590-6597.
131 Ralph A.Tripp,Les P.Jones, Lia M. Haynes,et al.CX3C chemokine mimicry by respiratory syncytial virus G Glycoprotein[J].Nature immunology 2001,2(8):732-738.
132范昌发,龚伟,梅兴国,等.呼吸道合胞病毒G蛋白基因片段的克隆及高效表达[J].中国病毒学,2004,19(6):553-558.
133钟南山,黄海鹭,常汝虚,等.呼吸道合胞病毒G蛋白胞外区基因克隆及序列分析[J].2000,6(3):163-167.
134 Plotnicky H,Siegrist CA,Aubry JP,et al.Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate.Vaccine,2003,21:2651-1660.
135 Chen ZM ,Mao J H ,Du LZ ,et al . Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection[J].Acta Paediatr,2002,91: 914-922.
136 Zhang Y, Wang Y, Gilmore X, et al . An aged mouse model for RSV infection and diminished CD8 + CTL responses [J].Exp BiolMed (Maywood),2002,227(2):133-140.
137 KUMAR M ,KON G X,BEHERA A K, et al.Chitosan IFN-γgamma-pDNA Nanoparticle(CIN ) Therapy for Allergic A sthma [J].Genet Vaccines Ther,2003,1(1):3.
138陈晓琦,徐葛林.粘膜基因表达疫苗——新的呼吸道合胞病毒疫苗策略[J].国外医学预防诊断治疗用生物制品分册,2004,27(2):62-64.
2 Spann KM,Tran KC,Collins PL.Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor3, NF-kappaB,and proinflammatory cytokines[J].Virol,2005,79(9):5353-5362.
3 Murphy LB,Loney C,Murray J,et al.Investigations into the aminoterminal domain of the respiratory syncytial virus nucleocap sid protein reveal elements important for nucleocap sid formation and interaction with the phosphor protein[J].Virology,2003,307(1):143-153.
4 Lu B,Ma CH,Brazas R,et al.The major phosphorylation sites of the respiratory syncytial virus phosphop rotein are dispensable for virus rep lication in vitro[J].Virol,2002, 76(21):10776-10784.
5 Bukreyev A,Whitehead SS,Murphy BR,et al.Recombinant respiratory syncytial virus from which the entire SH gene has bee deleted grows efficiently in cell culture and exhibits site2secific attenuation in the respiratory tract of the mouse[J].Virol,1997,71(12): 8973-8982.
6李光,井申荣.呼吸道合胞病毒蛋白的研究进展[J].中国生物制品杂志,2006,19(5):541-547.
7 Rodriguez L,Cuesta I,Asenjo A,et al.Human resp iratory syncytial virus matrix protein is an RNA-binding protein:binding properties,location and identity of the RNA contact residues[J].Gen Virol,2004,85(3):709-719.
8 Tang RS,Nguyen N, Cheng X,et al.Requirement of cysteines and length of the human respiratory syncytial virusM2-1 protein for protein function and virus viability[J].Virol,2001,75(23):11328-11335.
9 Teng MN,Whitehead SS,Bermingham A,et al.Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees[J].Virol,2000,74(19):9317-9321.
10 Blount RE, Morris JA,Savage RE.Recovery of cytopqthogenic agent from chinmpanzees with coryza[J].Proc Soc Exp Biol Med,1956,92(3):544-549.
11曾瑞红.RSV重组蛋白疫苗的制备及其免疫原性和保护性研究[J].军事医学科学院博士学位论文,2006:6.
12 Mohamed H,Caroline B.Respiratory syncytial virus in healthy adults:the cost of a cold[J].J Clin Vir,2003,27:14 - 21.
13范行良,周铁群.呼吸道合胞病毒F蛋白研究进展[J].微生物学免疫学进展,2004,32(4):73-76.
14芦起,谢正德,申昆玲.呼吸道合胞病毒的蛋白特征及抗原变异[J].国外医学病毒学分册,2005,12(3):76-80.
15 L.Goetsch,H.Plotnicky-Gilquin,J.P.Aubry,et al.BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice[J].Vaccine,2001(19):4036-4042.
16 Beeler JA,Van Wyke CK.Neutralization epitopes of the F glycoprotein of respiratory syncytial virus:effect of mutation upon fusion functio〔J〕Virol,1989,63(7): 2941-2950.
17孔晓慧,江载芳.人类呼吸道合胞病毒粘附(G)蛋白的研究进展[J].国外医学分册,1999,6(3):77-81.
55李忠明.当代新疫苗学[M].高等教育出版社,2001.
19丁媛,赵晓东.机体抗呼吸道合胞病毒免疫机制研究进展[J].国际儿科学杂志,2006,33(1)志:14-17.
20 Gill MA,Palucka KA,Barton T,et al.Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytialvirus and other viral respiratory infections[J].J Infect Dis,2005,191(7):1105-1115.
21 Murphy BR,et al.Immunization of cotton ratsw ith the fusion(F) and large (G)glycol proteins of respiratory syncytial virus protects against respiratory syncytial virus challenge without potenting RSV disease[J].Vaccine,1989,7(6):533～540.
22 Bendelja K,Gagro A,Bace A,et a1.Predominant type-2 response in infants with respiratory syncytial virus(RSV)infection demonstrated by cytokine flow Cytometry[J].Clin Exp Immunol,2000,121(2):332-338.
23 Elliott MB,Tebbey PW,Pryharski KS,et al.Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES(CCL5)[J].J Med Virol,2004,73(2):300-308.
24 Kollerl MF,Graul T,Christen P.Induction of antibodies agaist murine full-length prion protein in wild-type mice[J].J of Neuroimmunology,2002,132:113-116.
25 Binde RJ,Han DK,Srivastava PK.CD91:a receptor for heat shock protein gp96[J].Nat Immunol,2000,1:151-155.
26 Srivastava PK,Amato RJ.Heat shock proteins:the‘Swiss Army Knife’vaccines againstcancers and infectious agents.Vaccine,2001,19:2590-2597.
27林林,王佑春,李富德.呼吸道合胞病毒(RSV)感染预防的研究进展[J].国外医学病毒学分册,2003,10(3):82-89.
28周娟,崔玉霞,杨锡强,等.特异性反义寡核苷酸抗小鼠呼吸道合胞病毒感染的研究[J].第三军医学学报,2007,29(2):112-116.
29崔玉霞,杨锡强.呼吸道合胞病毒感染及反义基因治疗的研究进展[J].中华儿科杂志,2006, 44(8):629-632.
30 Yu JY,Deruiter SL,Tumer DL.RNA interference by expression of short interfering RNAs and hairpin RNAs in mammalian cells[J].Proc Natl Acad Sci USA,2002,99: 6047-6052.
31 Plotnicky H,Siegrist CA,Aubry JP,et al.Enhanced pulmonary immunopathology following neonatal priming with formalin-inativated respiratory syncytial virus but not with the BBG2Na vaccine candidate[J].Vaccine,2003,21:2615-2660.
32 Hancock GE ,Heers KM,Pryharski KS,et al . Adjuvants recognized by Toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytialvirus[J]. Vaccine ,2003,21(27- 30):4348-4358.
33 Olson MR,Varga SM.Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease[J].J Immunol,2009,182(5):3024-3031.
34 Julian P.Legg,Imran R.Hussain,Jill A.Warner, et al.Type 1 and Type 2 Cytokine Imbalance in Acute Respiratory Syncytial Virus Bronchiolitis[J].AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE,2003,168:633-639.
35 F.Eun-Hyung Lee,Edward E.Walsh,Ann R.Falsey, Human Infant Respiratory Syncytial Virus(RSV)–Specific Type 1 and 2 Cytokine Responses Ex Vivo during Primary RSV Infection[J].JID,2007,195(15):1779-1788.
36 Marc PG,Thomas C,Yuri P,et al.A review of vaccine research and development:Human acute respiratory infections[J].Vaccine,2005,23:5708.
37芦起,谢正德,许文波,等.呼吸道合胞病毒亚单位疫苗的研究进展[J].世界核心医学期刊文摘·儿科学,2005,1(9):1-4.
38 Tristram DA,Welliver RC,Mohar CK,et al. Immunogenicity and safety of respiratory syncytial virus virus subunit vaccine in seropositive children 18-36 months old[J]. Infect Dis,1993,167:191-195.
39 Falsey A R. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine(PFP-2)in the institutionalized elderly[J].Vaccine,1997,15(IO): 1130-1132.
40 Munoz.F M. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women[J].Vaccine 2003,21:3465-3467.
41 Hancock GE,Smith JD,Heers KM.Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus[J].Infect Dis,2000,81:1786-1771.
42 Piedra PA,Cron SG, JewellA, et al.Immunogenicity of a new purified fusionprotein vaccine to respiratory syncytial virusa multi2center trial in childrenwith cystic fibrosis[J].Vaccine,2003,21(19-20):2448-2460.
43 Kim HJ,Kim JK,Seo SB,et.al.Intranasal vaccination with peptides and cholera toxin subunit B as adjuvant to enhance mucosal and systemic immunity to respiratory syncytial virus[J].Arch Pharm Res,2007,30(3):366-371.
44 Shree R.Singh.Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model[J].Vaccine,2007,14:6211-6223.
45 Zhan X,Hurwitz JL,Krishnamurthys,et,al.Respiratory syncytial virus(RSV)fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B[J]. Vaccine,2007,25(52):8782-8793.
46 Power UF,Nguyen TN,Rietveld E,et al.Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine(BBG2Na) in healthy young adults[J].J Infect Dis,2001,184:1456-1460.
47徐军,胡云章.呼吸道合胞病毒疫苗研究进展.生物技术通讯,2007,18(2):310-312.
48 Power UF,Plotnicky H,Blaecke A,et al.The immunogenicity,protective efficacy and safety of BBG2Na,a subunit respiratory syncytial virus(RSV) vaccine candidate, against RSV-B,Vaccine,2003,22:168-176
49 De Waal L,Brideau RJ,Thomsen DR,et al.Evaluation of BBG2Na in infant macaques:specific immune responses after vaccination and RSV challenge[J].Vaccine,2004,22:915-922.
50 Prince GA,Denamur F,Deschamps M,et al.Monophosphoryl lipid Aadjuvant reverses a principalhistologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease[J].Vaccine 2001,19(15-16):2048-2054.
51 Klinguer-Hamour C,Libon C,Plotnicky-Gilquin H,et al. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine[J].Vaccine 2002,20(21-22):2743-2751.
52 Huang Y. Anderson R Enhanced immune protection by a liposomeencap sulated recombinant respiratory syncntial virus(RSV) vaccine using immunogenic lipids from Deinococcus radiodurans[J].Vaccine,2002,20(11-12):1586-1592.
53 Roux X. Sub-Nucleocapsid Nanoparticles:A Nasal Vaccine against Respiratory Syncytial Virus[J].PLoS ONE,2008,3(3):1766.
54 Matthews N C,Power U F,Reen D J.Neonatal human autologous dendritic cells pulsed with recombinant protein antigen prime the generation of non-polarized CD4 T-cell effectors[J].Int Immunol,2007,19(6):703-712.
55 Yusibov V,Mett V,Mett V,et al.Peptide-based candidate vaccineagainstrespiratory syncytial virus[J].Vaccin,2005,23(17/18):2261-2265.
56 Ward TM.Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic[J].Gen Virol,2008,89(3):741-750.
57 Wathen MW, Brigeau RJ.Thomsen DR, et al.Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector [J].Gen virol 1989,70:2625-2635.
58 Prince GA,Capiau C,Deschamps M,et al.Efficacy and safety studies of studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats [J].Virol 2000,74:10287-10292.
59 Oien NL,Brideau RJ,Thomsen DR,et al.Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity[J].Vaccine 1993,11:1040-1048.
60 Oien NL,Brigeau RJ,Walsh EE, et al.Induction of local and systemic immunity against human respiratory syncytial virus using chimeric FG glycoprotein and cholera toxin B subunit[J].Vaccine,1994,12:731-735.
61 Polack FP,Karron RA. The future of respiratory syncytial virus vaccine development[J]. Pediatr Infect Dis,2004,23(1):65-73.
62 Juhasz K,Whitehead ss,Bui RT,et al.The temperature-sensitive(ts) phenotype of a cold-passaged(cp) live attenuated respiratory syncytial virus vaccine candidate,designated cpts530,result S from a single amino acid substitution in the L Protein[J].J virol,1997,71(8):5814-5819
63 Gonzalez IM,Karron RA,Eichelberger M,et al.Evaluation of the live attenuated cpts
248/404 RSV Vaccine in ombination vith a subunit RSV vaccine(PFP-2)in healthy young and older adults[J].Vaccine,2000,18(17):1763-1772.
64 Crowe JE, Randolph V.Murphy BR.The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees,but exhibits partial loss of the ts phenotype following relication in vivo[J].Virus Res,1999,59(1):13-22.
65 Whitehead SS,Bukreyev A,Teng MN,et al.Recombinant respiratory syncytial virus bearing a deletion of either the or SH gene is attenuated in chimpanzees[J],J Virol,1999,73(4):3438-3442.
66 TengMN,Whitehead SS,Bermingham A,et al.Recombinant respiratory syncytial virus that does not express the NS1or M2-2 protein is highly attenuated and immunogenic in chimpanzees[J].J Virol,2000,74(19):9317-9321.
67 Rodriguez WJ,Gruber WC,Welliver RC,et al.Respiratory syncytial virus(RSV)immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections:Respiratory Syncytial Virus Immune Globulin Study Group[J].Pediatrics,1977,99(3):454-461.
68 Whitehead SS, HillMG, Firestone CY,et al.Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup Awith those of subgroup B generates chimeric live attenuated RSVsubgroup B vaccine candidates[J].J Virol,1999,73 (12) : 9773-9780.
69 OlszewskaW,Suezer Y,Sutter G,et al.Protective and disease2enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins[J].Vaccine,2004,23(2):215-221.
70 Sandhu JS,rasnyansk i SF,Dom ier LL,et al.T ransgenic Res,2000,9(2):127-135
71 Bembridge GP,Rodriguez N,Garcia-Beato R,et al.Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment(G)protein[J]. Vaccine,2000, 19(9210):1038-1046.
72苏荣,王立波.呼吸道合胞病毒疫苗的研究进展[J].国际儿科学杂志,2006,33(3):187-190.
73吴小锋,岳万福,刘剑梅,等.Bac-to-Bac系统的研究进展及在家蚕中的应用[J].蚕业科学, 2007,33(1):146-150.
74 Gerald E.Hancock,Honeoye Falls,Paul W.Tebbey,et al.Enhanced immune response to attachment (G) protein of respiatory syncytial virus[P].US:6,699,478,2004,2.
75刘菊,杨春,唐安芬,等.呼吸道合胞病毒Long株的培养及应用[J].微生物学杂志,2004, 24(5):47-49.
76 Pammivenkatesh M, Weisman LE. Prevention and treatment of respiratory syncytial virus infection infants:an update[J].Expert Rev Vaccine,2006,5(2):261-268.
77卢圣栋主编.现代分子生物学实验技术[M].第二版.北京:中国协和医科大学出社,1999, 80-149,233-292.
78 Subel FM,Brent R,Kingston RE,et al.精编分子生物学实验指南[M],北京:科学出版社,1998.
79 Simoes EA ,Carbonell - Estrany X.Impact of severe disease caused by respiratory syncytial virus in children living in developed countries[J].Pediatr Infect Dis J,2003,22(2):13-18.
80曾瑞红,龚伟,梅兴国,等.呼吸道合胞病毒重组蛋白DsbA2G1F/M2的制备方法及免疫原性研究[J].中国药学杂志,2007,42(2):90-93.
81 M c Into sh K,Chanock R. Resp irato ry Syncytial V irus B N F ields et al[J]. Virology Raven Press, New York.1990,1045-1072.
82 Welliver R C.Respiratory syncytial virus and other Respiratory viruses[J].Pediatr Infect Dis J,2003,22(2):6～12.
83袁媛,何金生,张梅,等.人呼吸道合胞病毒F基因的克隆、真核表达与鉴定[J].免疫学杂志,2006,22(3):330-333.
84 Johnson T R,TengM N, Collins PL,et al.Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine2enhanced disease induced by immunization with formalin inactivated RSV[J].J Virol,2004,78(11):6024-6032.
85 Cane P A ,Matthews D A ,Pringle C R. Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial virus[J].J Gen Virol, 1991,72:2091-2096.
86 Cane P A. Molecular epidemiology of respiratory syncytial virus[J].Rev Med Virol, 2001,11(2):103-316.
87 Plotnicky-Gilquin H,Cyblat-Chanal D,Aubry JP,et al.Gamma interfereon dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment[J].J Virol,2002,76(20):10203.
88 IMartinez,J Dopazo and J A Melero. Antigenic structure of the human respiratory syncytial virus Gglyxoprotein and relevance of hypermutation events for the generation of antigenic variants[J].Journal of General virology 1997,78:2419.
89 Kneyber M C, Kimpen J L. Advances in respiratory syncytial virus vaccine development [J].Curr Opin Investig Drugs,2004,(5):163-170.
90耿学辉,王之梁,钱渊,等.呼吸道合胞病毒北京地区分离株G蛋白的基因分析[J].1996,12(4):317-322.
91邓洁,孙晓鸥,钱渊,等.中国呼吸道合胞病毒地方株G蛋白在重组痘苗病毒中的表达[J].中华微生物学和免疫学杂志,2004,24(4):284-286.
92邓洁,王之梁,钱渊,等.我国流行性喘憋性肺炎呼吸道合胞病毒分离株F蛋白基因特征初探[J].中华儿科杂志,1999 37(5):287-290.
93曾瑞红,梅兴国,龚伟,等.RSV CTL表位与G蛋白片段的融合表达对G蛋白片段诱导的免疫应答的调节作用[J].分子与细胞免疫学,2007,23(5):387-390.
94曾瑞红,梅兴国.RSV CTL表位与G蛋白片段的融合表达对G蛋白片段诱导的免疫应答的调节作用[J].中国免疫学杂志,2007,23(5):387-390.
95熊蕊,邓国华,黎玉梅,等.H5亚型禽流感病毒HA基因杆状病毒载体的构建[J].黑龙江畜牧兽医,2007(5):15-17.
96 MARK PARRINGTON,STEPHEN COCKLE.Baculovirus Expression of the Respiratory Syncytial Virus Fusion Protein using Trichoplusia ni Insect Cells.Virus Genes[J].Virus Genes,1997,14(1):63-72.
97 Hancock GE,Heers KM. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)[J].Vaccine.2001,19(32):4874-4882.
98顿继凤,周迎春,蒲娟,等.H5N1亚型禽流感病毒血凝素在昆虫杆状病毒系统中表达与活性鉴定[J].农业生物技术学报,2007,15(4):547-551.
99贾珊珊,孙凌霜,齐岩,等.H7亚型禽流感病毒HA1基因在重组杆状病毒中的表达及其表达产物的抗原性[J].中国兽医科学,2007,37(3):232-235.
100袁建琴,高斌战,宋宝敏.H9N2型禽流感病毒HA基因在昆虫/杆状病毒系统中的表达[J].山西农业大学学报(自然科学版),2007,27(1):71-74.
101 Elisa H.Fleming,Andrey A.Kolokoltsov,Robert A.Davey,et al.Respiratory Syncytial Virus F Envelope Protein Associates with Lipid Rafts without a Requirement for Other Virus Proteins[J].JOURNAL OF VIROLOGY,2006,80(24):12160-12170.
102汪家政,范明主编.蛋白质技术手册[M].北京:科学出版社.2008.8.
103 Christine Krempl,Brian R.Murphy,Peter L.Collins.Recombinant Respiratory Syncytial Virus with the G and F Genes Shifted to the Promoter-Proximal Positions[J].JOURNAL OF VIROLOGY,2002,76(23):11931-11942.
104林董.RSV五个基因及GFP-CP、GFP-SP融合基因在Sf9昆虫细胞中的表达[D].福建:福建农林大学,2007.
105 Power U F,Plotnicky-Gilquin H, Huss T et al.Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment[J].Virology,1997, 230:155-166.
106殷震,刘景华主编.动物病毒学[M].第二版.北京:科学出版社,P329-331.
107 Patricia Sastre,Antonius G.P.Oomens,Gail W.Wertz.The stability of human respiratory syncytial virus is enhanced by incorporation of the baculovirus GP64 protein[J]. Vaccine,2007,(25):5025-5033.
108朱立平.免疫学常用实验方法[M].北京:民军医出版社,2000.
109 Janak A.Patel,Dang T.Nguyen,Krystal Revai,et al.Role of respiratory syncytial virus in acute otitis media:Implications for vaccine development[J].Vaccine, 2007,25:1683—1689.
110 R.Marsh,A.Connor,E.Gias,et al.Increased Susceptibility of Human Respiratory Syncytial Virus to Neutralization by Anti-Fusion Protein Antibodies on Adaptation to Replication in Cell Culture[J].Journal of Medical Virology 2007(79):829-837.
111 Sonya L.Cyr,Taff Jones,Ioana Stoica-Popescu.C57Bl/6 mice are protected from respiratory syncytial virus (RSV)challenge and IL-5 associated pulmonaryeosinophilic infiltratesfollowing intranasal immunization with Protollin-eRSV vaccine[J].Vaccine,2007,(25):3228-3232.
112韩岳,王希良,董梅,等.tPA信号肽和鼠疫杆菌保护性抗原V融合基因的构建及免疫效果鉴定[J].现代免疫学,2006,26(6):477-482.
113韩岳,王希良,董梅,等.鼠疫菌重组质粒pcDNATEPF12V的构建及其免疫效果的研究[J].免疫学杂志,2005,21(3):208-211.
114吕进,张松乐,董梅.炭疽AVA疫苗特异性抗体分泌细胞检测方法的建立[J].免疫学杂志, 2007,23(4):452-455.
115 Whitmire J K,Asano M S Murali-Krishna K,et al.Long term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infection[J].J Virol,1998, 72(10):8281—8288.
116 Openshw PJW.Immunity and immunopathology to respiratory sycytial virus:the mouse modl[J]e.Am J Respir Crit Care Med,1995,152:59-62.
117董德祥主编.疫苗技术基础与应用[M].北京:化学工业出版社,2003,102-148.
118曾瑞红,梅兴国,龚伟,等.RSV CTL表位与G蛋白片段的融合表达对G蛋白片段诱导的免疫应答的调节作用[J].分子与细胞免疫学,2007,23(5):387-390.
119 Sonya L.Cyr,Taff Jones,Ioana Stoica-Popescu,et al.Intranasal proteosome-based respiratory syncytial virus (RSV)vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology[J].Vaccine,2007,25,5378-5389.
120 Elliott MB ,Tebbey PW,Pryharski KS ,et al.Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES(CCL5)[J].J Med Virol,2004,73(2):300-308.
121 Mosmann T R,Sad S.The expanding universe of T-cell subset:Th1,Th2 and more[J]. Immunol Today,1996,17:138-146.
122 Shirai A,Homes K,Klinman D M,et al.Detection and quantitation of cells secreting IL26 under physiologic conditions in BALB/c mice[J].Immunol,1993,150:793-799.
123毕爱华主编.医学免疫学[M].北京:民解放军出版社,1997,24-92.
124 Kolaskar AS,Tongaonkar PC A semi-empirical method for prediction of antigenic determinants on protein antigens[J].FEBS Lett.1990,276(1-2):172-174.
125 Alexander Bukreyev,Maria Elina Serra,Federico R.Laham,et,al.The Cysteine-Rich Region and Secreted Form of the Attachment G Glycoprotein of Respiratory Syncytial Virus Enhance the Cytotoxic T-Lymphocyte Response despite Lacking Major Histocompatibility Complex Class I-Restricted Epitopes[J].Journal of Virology,June 2006,80(12):5854-5861.
126 Jennifer Harcourt, Rene Alvarez, Les P. Jones,et al.Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses[J].The Journal of Immunology,2006,176:1600-1608.
127 Ultan F.Power,Liliane Goetsch,Thierry Champion,et al.Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein[J].Vaccine,2001,19:2345-2351.
128王云飞,曾瑞红,梅兴国.免疫A型呼吸道合胞病毒G75-225蛋白的小鼠对病毒感染的抗性[J].生物技术通讯,2006,17(3):352-354.
129余莉,龚蕴贞.呼吸道合胞病毒模拟表位合成肽疫苗的开发[J].国外医学预防诊断治疗用生物制品分册,2002,25(5):199-201.
130 ANON SRIKIATKHACHORN,WILBUR CHANG,THOMAS J.BRACIALE.Induction of Th-1 and Th-2 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope and Major Histocompatibility Complex Independent[J].JOURNAL OF VIROLOGY,1999, 73(8):6590-6597.
131 Ralph A.Tripp,Les P.Jones, Lia M. Haynes,et al.CX3C chemokine mimicry by respiratory syncytial virus G Glycoprotein[J].Nature immunology 2001,2(8):732-738.
132范昌发,龚伟,梅兴国,等.呼吸道合胞病毒G蛋白基因片段的克隆及高效表达[J].中国病毒学,2004,19(6):553-558.
133钟南山,黄海鹭,常汝虚,等.呼吸道合胞病毒G蛋白胞外区基因克隆及序列分析[J].2000,6(3):163-167.
134 Plotnicky H,Siegrist CA,Aubry JP,et al.Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate.Vaccine,2003,21:2651-1660.
135 Chen ZM ,Mao J H ,Du LZ ,et al . Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection[J].Acta Paediatr,2002,91: 914-922.
136 Zhang Y, Wang Y, Gilmore X, et al . An aged mouse model for RSV infection and diminished CD8 + CTL responses [J].Exp BiolMed (Maywood),2002,227(2):133-140.
137 KUMAR M ,KON G X,BEHERA A K, et al.Chitosan IFN-γgamma-pDNA Nanoparticle(CIN ) Therapy for Allergic A sthma [J].Genet Vaccines Ther,2003,1(1):3.
138陈晓琦,徐葛林.粘膜基因表达疫苗——新的呼吸道合胞病毒疫苗策略[J].国外医学预防诊断治疗用生物制品分册,2004,27(2):62-64.